Daisuke Ishikawa

Kanazawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 16, 2014

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.

Journal: Oncology reports

Published: September 21, 2013

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.

Journal: PloS one

Published: August 26, 2013

Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.

Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.

Journal: JOP : Journal of the pancreas

Published: June 26, 2013

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

Journal: Cancer research

Published: February 06, 2013

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Journal: PloS one

Published: November 29, 2012

A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan

A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: September 22, 2012

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Journal: International journal of cancer

Published: August 27, 2012

Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective

Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 21, 2012

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Journal: Molecular cancer therapeutics

Published: July 31, 2012

Different sensitivity to chemotherapy between adenocarcinoma and adenosquamous carcinoma in a case of synchronous multicentric gastric cancer

Different sensitivity to chemotherapy between adenocarcinoma and adenosquamous carcinoma in a case of synchronous multicentric gastric cancer

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: March 09, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026